Platelet Mitochondria: A Promising Target for Antiplatelet Therapy
Antioxidants & Redox Signaling · 2026
DOI: 10.1177/15230864261452350 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants & Redox Signaling, 2026. Verfasst von Yan-Zhu Yao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Geriatrics, Beijing Key Laboratory of Aging and Geriatrics, National Clinical Research Center for Geriatric Diseases, Second Medical Cen…. Hauptthemen laut MEDLINE: Mitochondria, Blood Platelets, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 212 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Significance: Platelet mitochondria drive platelet activation and thrombosis by fueling energy demands via metabolic reprogramming, regulating calcium-mediated procoagulant signaling, and maintaining functional integrity through quality control mechanisms. Current antiplatelet agents, including P2Y12 antagonists, cyclooxygenase-1 inhibitors, glycoprotein IIb/IIIa blockers, and protease-activated receptor-1 antagonists, effectively prevent thrombosis but increase bleeding risk, underscoring the need for metabolism-targeting strategies. Recent Advances: Here, we summarize key platelet mitochondrial mechanisms driving platelet activation: metabolic reprogramming through oxidative phosphorylation (OXPHOS)-to-glycolysis shifts, calcium flux mediated by the mitochondrial calcium uniporter controlling coagulation, quality control through dynamics and mitophagy, and mitochondrial genome (mtDNA) regulation linked to relevant diseases. Critical Issues: The variable role of OXPHOS in thrombosis remains incompletely understood. Metabolic flexibility complicates therapeutic intervention, while the cytotoxic effects of mitochondrial modulators and technical limitations in the quantification of circulating mtDNA present significant translational challenges. Future Directions: Development of therapies based on mitochondria-targeted antioxidants and metabolic enzyme modulators is proposed as a promising antiplatelet strategy. Transplantation of platelet-derived mitochondria and standardized detection of mtDNA warrant further exploration for thrombotic diseases. Antioxid. Redox Signal. 45, 265–292.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Geriatrics, Beijing Key Laboratory of Aging and Geriatrics, National Clinical Research Center for Geriatric Diseases, Second Medical Center of the Chinese PLA General Hospital, Beijing, China.
- Medical Innovation Research Division and Fourth Medical Center of the Chinese PLA General Hospital, State Key Laboratory of Trauma and Chemical Poisoning, Beijing, China.
ORCID-Profile: Yong-Ming Yao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yao, Y. Z., Yin, T., & Yao, Y. M. (2026). Platelet Mitochondria: A Promising Target for Antiplatelet Therapy. Antioxidants & Redox Signaling. https://doi.org/10.1177/15230864261452350
Vancouver
Yao YZ, Yin T, Yao YM. Platelet Mitochondria: A Promising Target for Antiplatelet Therapy. Antioxidants & Redox Signaling. 2026. doi:10.1177/15230864261452350
BibTeX
@article{Yao2026,
author = {Yao, Yan-Zhu and Yin, Tong and Yao, Yong-Ming},
title = {Platelet Mitochondria: A Promising Target for Antiplatelet Therapy},
journal = {Antioxidants & Redox Signaling},
year = {2026},
doi = {10.1177/15230864261452350}
}
EUVIMED